We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in ...

JNJ's acquisition of ITCI is strategic, replacing its aging Invega with Caplyta, which has patent protection until 2033 and ongoing clinical trials for new formulations. The $14 billion price tag ...

Below is Validea's guru fundamental report for INTRA-CELLULAR THERAPIES INC (ITCI). Of the 22 guru strategies we follow, ITCI rates highest using our Quantitative Momentum Investor model based on ...

Intra-Cellular Therapies ITCI reported fourth-quarter 2024 loss of 16 cents per share, wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had incurred a loss of 29 cents per ...

Charles Schwab Investment Management Inc. raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 0.2% in the fourth quarter, according to the company in its most recent ...

1 Day ITCI 0.04% DJIA -0.05% S&P 500 0.06% Health Care/Life Sciences 0.13% ...

In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in ...

1 Day ITCI 0.02% DJIA 0.95% S&P 500 1.35% Health Care/Life Sciences 0.13% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...